Skip to content

Generalized Anxiety Disorder Symptom Improvement Following Mindfulness-Based Stress Reduction in a General Hospital Setting

Holly Hazlett-Stevens

Journal of Medical Psychology November 6, 2020 DOI: 10.3233/jmp-170012 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational pre-post study Randomized Peer reviewed
Sample size 19
Population Patients enrolled in a general hospital MBSR program who reported moderate to severe GAD symptoms at the first session
Measures GAD-7, Penn State Worry Questionnaire (PSWQ), DASS21 Anxiety, DASS21 Stress
Topics Anxiety Meditation
Key findings Among 19 patients with moderate to severe GAD symptoms who completed a general hospital MBSR course, anxiety and stress symptoms fell significantly from pre- to post-MBSR, with large effects on the GAD-7 (d = 1.95) and DASS21 Stress (d = 1.31); 79% scored below the GAD-7 screening cutoff at the final session and 47% showed clinically significant improvement on the PSWQ. The authors conclude MBSR may be an acceptable and effective treatment option for GAD patients in medical settings.

Abstract

Background: GAD symptom complaints are common in general medical settings, yet psychosocial intervention options provided within such settings are limited. Randomized controlled trials have found that MBSR is effective for symptom reduction, but such research typically delivered MBSR to small diagnostically homogeneous patient groups rather than to larger heterogeneous groups as provided in medical settings.

Objective: The current research examined what proportion of patients already enrolled in a general hospital MBSR program presented with symptoms of GAD and whether such symptoms reduced after delivering MBSR in large diagnostically heterogeneous groups.

Methods: Twenty-six (40%) of 65 participants enrolled in a large hospital MBSR program indicated moderate to severe GAD symptom severity at the first MBSR session. Of these, 19 voluntarily completed brief self-report measures at the beginning and end of their MBSR course.

Results: Statistically significant reductions pre to post-MBSR were found on the GAD-7 (Cohen’s d = 1.95), Penn State Worry Questionnaire (Cohen’s d = 0.76) and the DASS21 Anxiety (Cohen’s d = 0.71) and Stress (Cohen’s d = 1.31) scales. Fifteen (79%) GAD participants scored below the GAD-7 screening measure cutoff at the final MBSR session. Forty-seven percent showed clinically significant improvement on PSWQ scores.

Conclusions: MBSR, as typically delivered in general hospital settings, may provide an acceptable and effective treatment option for GAD patients seeking care in medical settings.

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Explore topics